Scicasts (press release) (registration) (blog) |
Anti-IL-5 Cuts Exacerbations in Eosinophil Asthma
MedPage Today In one of the studies, the clinical asthma exacerbation (CAE) rate was halved (rate ratio 0.50, 95% CI 0.37-0.67, P<0.0001) among patients receiving reslizumab compared with those given placebo, reported Mario Castro, MD, MPH, of Washington University … Investigational drug can reduce asthma flareups Investigational biologics among emerging therapies for severe asthma Investigational Drug Could Reduce Asthma Flareups |
View full post on asthma – Google News